← Back to all trials
Not Yet Recruiting
NCT07706673
A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano [VPH]")
Conditions: Human Papillomavirus-Related Malignant Neoplasm
Sex: Female
Ages: 12 Years – N/A
Healthy volunteers: Yes
Enrollment: 9700
Sponsor: National Cancer Institute (NCI)
Location: Agencia Costarricense de Investigaciones Biomédicas (ACIB) Liberia Guanacaste Province
Summary
This study evaluates the long term protection provided by either one or two doses of the HPV vaccine for patients who were part of the ESCUDDO study.
Eligibility Criteria
Inclusion Criteria:
* \* Participation in ESCUDDO base study
* Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms
* A signed informed consent form for ESCUDDO LTFU.
* Opportunity to complete three total study visits
Exclusion Criteria:
* \* Enrollment cannot occur beyond her 10 year study visit
Source: ClinicalTrials.gov (NCT07706673). StuddyBuddy aggregates publicly available trial information.
